GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A new review suggests that tirzepatide (Mounjaro, Zepbound) may have neuroprotective mechanisms that could help reduce the ...

Addex Scientists Discover Glucagon-like-peptide-1 (GLP-1) Induced Interaction Between GLP-1 and Gastric Inhibitory Peptide (GIP) Receptors Mon Nov 28, 2011 1:02am EST Addex Pharmaceuticals / Addex ...

The Mounjaro-like anti-obesity prescription drug Zepbound is now available at pharmacies. Health experts provide clear answers to common questions about the newest GLP-1 weight loss medication.

Advances in drug design, such as dual and triple agonists (e.g., GLP-1/gastric inhibitory peptide (GIP) and GLP-1/GIP/glucagon receptor agonists), are expanding the therapeutic impact of these ...

"IMU-856's target, SIRT6, is highly expressed in cells of the bowel wall, including enteroendocrine cells, which produce gastrointestinal hormones such as GLP-1 and gastric inhibitory peptide (GIP).

Novo Nordisk and Septerna will jointly initiate four preclinical development programmes, targeting well-established metabolic receptors for glucagon-like peptide 1 (GLP-1), gastric inhibitory ...

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

Inhibitory effect of C-type natriuretic peptide on spontaneous contraction in gastric antral circular smooth muscle of rat. Acta Pharmacol Sin 2003; 24 : 1021–6. CAS PubMed Google Scholar ...